DRI Healthcare Trust reported quarterly earnings of C$0.53 per unit, below the C$0.77 estimate. At the same time, the Trust reported year-over-year growth in cash receipts and Adjusted EBITDA.
DRI Healthcare Trust (TSX: DHT.UN) released results after market close on November 4 for the quarter ended September 30, 2026. Calendar data shows earnings per unit of C$0.53, 31.2% below the C$0.77 estimate. The company’s release, as summarized in supplemental coverage, also reported that normalized cash receipts and Adjusted EBITDA each rose 9% from a year earlier. For Canadian investors, the estimate miss and the Trust’s cash-generation measures tell different parts of the story.
Recent earnings trend
DRI Healthcare Trust
DHT-UN.TO
DHT-UN.TO
DRI Healthcare Trust
WealthAwesomeMarket cap
$1.08B
P/E
13.2x
Div. yield
0.53%
Div. / share
$0.10
52W high
$19.58
52W low
$14.61
1W change
+6.01%
Beta
0.54
Analyst Price Targets
Based on analyst covering DHT-UN · as of Nov 9, 2026
Wall Street analysts forecast DHT-UN stock price to rise 26.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$24.29
+26.3% Upside
Previously C$23.98 on Nov 6, 2026
Current Price
C$19.23
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on DHT-UN's historical volatility
30-Day Vol
14.3%
Annualized
90-Day Vol
23.1%
Annualized
Trend (90d)
+18.1%
Annualized drift
90d Mean
C$20.51
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$19.65 | C$18.70 – C$20.64 |
| 60 trading days | C$20.08 | C$18.73 – C$21.52 |
| 90 trading days | C$20.51 | C$18.84 – C$22.34 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 4 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 2 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-12-31 | 2027-03-03 | — | 0.5600 | — |
| 2026-09-30 | 2026-11-04 | 0.5300 | 0.7700 | -31.2% |
| 2026-06-30 | 2026-08-07 | 0.5600 | 0.6000 | -6.7% |
| 2026-03-31 | 2026-05-14 | 0.6800 | 0.5500 | +23.6% |
| 2025-12-31 | 2026-03-03 | 0.7800 | 0.5200 | +50.0% |
| 2025-09-30 | 2025-11-05 | 0.5500 | 0.5500 | +0.0% |
Investor takeaway: DRI missed the earnings estimate, but the available summary points to higher cash receipts and Adjusted EBITDA. The Trust has missed estimates in two of its last four comparable quarters. Consider the latest result alongside its recent record and outlook, rather than treating one earnings figure as the full picture. The information provided does not include a full explanation of the miss or detailed revenue and margin results.
C$0.53 earnings per unit versus C$0.77 expected
DRI fell C$0.24 per unit short of the estimate, a 31.2% miss. In the prior quarter, it reported C$0.56 against C$0.60 expected. The quarter before that, it reported C$0.68, beating the C$0.55 estimate. The automatically inserted earnings trend table and chart show the results by quarter.
Bull case
Normalized cash receipts and Adjusted EBITDA each reportedly rose 9% year over year. DRI also expects 2026 Adjusted EBITDA to exceed the high end of its previous US$157 million to US$162 million range. The Trust added a tavapadon royalty agreement with fixed payments, tiered royalties and milestones. Supplied market data also shows DHT-UN.TO units trading above their 50- and 200-day moving averages.
Bear case
Earnings came in 31.2% below consensus, and DRI missed estimates in two of its last four reported quarters. The US$14.6 million non-cash impairment tied to Zejula highlights the risk of setbacks affecting individual assets in a royalty portfolio. The next-quarter earnings estimate has also fallen from C$0.57 to C$0.55 over the past 30 days, with more downward than upward revisions.
What the quarterly results show
For the quarter ended September 30, DRI reported calendar earnings per unit of C$0.53, compared with the C$0.77 estimate. The 31.2% miss is the main headline, but it is not the only signal in the available results. Supplemental coverage of the Trust’s November 4 release says normalized cash receipts were US$47.5 million and Adjusted EBITDA was US$40.0 million, each up 9% year over year. DRI also reported a US$14.6 million non-cash impairment tied to Zejula.
The information provided does not include a full explanation of the earnings miss, revenue figures or a margin breakdown. So it’s not possible to say whether the impairment explains the gap. DRI’s recent record is mixed: it beat estimates in two of its last four reported quarters, by 50% in December 2025 and 23.6% in March 2026, then missed in June and September. See the DHT-UN.TO stock page for more company and market data.
Outlook and recent royalty deals
According to the supplemental summary, DRI expects 2026 Adjusted EBITDA to exceed the high end of its previous US$157 million to US$162 million range. That outlook offers another point of comparison with the quarterly earnings miss. The Trust’s royalty portfolio generates cash flows tied to pharmaceutical products and agreements.
Recent activity includes a US$316 million purchase of U.S. tavapadon royalties. The agreement includes four annual fixed payments of US$23.4 million, tiered royalties and sales milestones, subject to a US$437.5 million cap. Separately, DRI received about US$178 million for its EKTERLY royalty in August, ending its participation right. These deals affect the mix of future receipts, which will depend on the contract terms and product performance.
For the next fiscal period, four analysts expect earnings per unit of C$0.55, down from C$0.57 30 days ago. Seven analysts expect revenue of US$45.30 million, a projected 7.1% decline from a year earlier. Over the same 30-day period, the data shows one upward and two downward earnings estimate revisions.
Analyst targets and price forecast
The average analyst target is C$24.29, compared with the supplied last close of C$19.23. That implies 26.3% upside to the average target, but it is an estimate, not a promise. The available context describes the consensus as bullish based on the target comparison; it does not provide a formal rating for this Canadian listing. See the analyst targets and ratings.
Wealth Awesome’s statistical 90-day model gives a mean forecast of C$20.51. Its 68% range is C$18.84 to C$22.34, and its 95% range is C$17.30 to C$24.33. This is a statistical model, not financial advice or a guarantee of future performance. See the price forecast section.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
